Primrose Bio, a San Diego biotech company, has begun a partnership to jointly develop and market products for mRNA medicines.
Interim data from the Phase I dose escalation part of the mRNA cancer immunotherapy (mRNA-4359), show promise in patients ...
Moderna's ability to launch differentiated mRNA therapies beyond covid, ranging from prophylactic vaccines for other respiratory diseases to cancer treatments, will be key to establishing a moat ...
Experimental mRNA cancer vaccine shows potential for advanced stage cancer patients in Phase 1 trial
Interim data from the Phase I dose escalation part of the mRNA cancer immunotherapy (mRNA-4359), show promise in patients with advanced solid cancers. The investigational mRNA cancer immunotherapy is ...
DNA (pDNA) purification system. PlasmidPro enables innovation at scale, providing complete automation across mini and maxi ...
The technique is called in vivo CAR-M therapy. "The nomination of the two autoimmune targets is a significant milestone in ...
ME Therapeutics to begin testing of first mRNA formulations from NanoVation Therapeutics collaboration: Vancouver, British Columbia Friday, September 20, 2024, 14:00 Hrs [IST] ME ...
Frustrated when Brazil could not get COVID vaccines, two Brazilian doctors (who have been best friends since college) decided ...
Cartesian Therapeutics, Inc.'s Descartes-08 mRNA CAR-T therapy shows promising Phase 2 results for myasthenia gravis without preconditioning chemotherapy. The company's RNA Armory platform enables ...
Results from the first-in-human trial of a new mRNA-based cancer vaccine are promising, as are early results from two other ...
Analyst Thomas Smith of Leerink Partners maintained a Buy rating on Cartesian Therapeutics (RNAC – Research Report), retaining the price ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback